CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 48 enrolled
Drug / intervention
Lenalidomidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00546897
NCT00546897Phase 2Completed
CompareCT.gov

Phase II Trial of Lenalidomide in Older Patients (>/= 60 Years) With Untreated Acute Myeloid Leukemia Without Chromosome 5q Abnormalities

Washington University School of Medicine·interventional·Posted Oct 19, 2007·Updated Sep 29, 2014

In Brief

A Phase 2 clinical trial evaluating Lenalidomide for Leukemia, Myeloid, Acute. Completed, enrolled 48 participants across 1 site.

Detailed Summary

This study is designed to test the safety and efficacy of lenalidomide in older patients (age \> 60 years) with untreated acute myeloid leukemia without chromosomal abnormalities involving 5q.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Myeloid, Acute
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 19, 2007
Enrollment StartFeb 1, 2007
Primary CompletionJun 1, 2010
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 18.7 years ago

Interventions

Lenalidomidedrug